Comparison of Tobramycin-Dexamethasone Combination Eyedrop Versus Artificial Tear Eyedrop for the Management of Presumed Viral Epidemic Conjunctivitis: A Randomized Treatment Trial.
Chintan Shah, Courtney F Goodman, Alok Sen, Deepak P Edward, Manish Tijare
{"title":"Comparison of Tobramycin-Dexamethasone Combination Eyedrop Versus Artificial Tear Eyedrop for the Management of Presumed Viral Epidemic Conjunctivitis: A Randomized Treatment Trial.","authors":"Chintan Shah, Courtney F Goodman, Alok Sen, Deepak P Edward, Manish Tijare","doi":"10.1080/02713683.2025.2515997","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To compare the efficacy and safety of one-time povidone-iodine (PovI) administration followed by a course of tobramycin-dexamethasone eye drops versus artificial tears in acute viral conjunctivitis (AVC).</p><p><strong>Methods: </strong>This was a single-centre, randomized controlled trial. Patients with AVC were instilled with PovI (5%) after proparacaine and then divided into two groups using a computer-generated random number table. Group A received combination drops of tobramycin(0.3%) and dexamethasone(0.5%), and group B received carboxymethylcellulose(0.5%) eyedrops. Both groups administered one drop four times daily for at least three days and until complete symptom resolution. A symptom score (SS) encompassing the five symptoms (redness, lid swelling, foreign body sensation, pain, watering; max score 15) was calculated at baseline, day 3, and day 7.</p><p><strong>Results: </strong>The study included 230 eyes (120 in group A, 110 in group B). There was a significant reduction in mean total SS at day 3 (2.16 ± 2.42) and day 7 (0.56 ± 1.14) in all eyes compared to at presentation (8.33 ± 2.46). At day 3, there was a lower mean total SS in group A (1.97 ± 2.31) compared to group B (2.36 ± 2.54) which was marginally significant (<i>p</i> = 0.086). At day 7, the proportion of eyes that were symptom-free was similar between groups (70.9%, <i>p</i> = 0.881). A multivariate analysis found that group B (OR = 2.08, <i>p</i> = 0.036) and a higher pain score (OR = 1.50, <i>p</i> = 0.046) were associated with a lack of clinical resolution by day 3.</p><p><strong>Conclusion: </strong>A course of tobramycin-dexamethasone combination eyedrops after PovI may lead to early symptomatic relief, but recovery was similar to artificial tears by day 7. No significant/sight-threatening complications were observed in any groups.</p>","PeriodicalId":10782,"journal":{"name":"Current Eye Research","volume":" ","pages":"994-1002"},"PeriodicalIF":2.0000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Eye Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02713683.2025.2515997","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To compare the efficacy and safety of one-time povidone-iodine (PovI) administration followed by a course of tobramycin-dexamethasone eye drops versus artificial tears in acute viral conjunctivitis (AVC).
Methods: This was a single-centre, randomized controlled trial. Patients with AVC were instilled with PovI (5%) after proparacaine and then divided into two groups using a computer-generated random number table. Group A received combination drops of tobramycin(0.3%) and dexamethasone(0.5%), and group B received carboxymethylcellulose(0.5%) eyedrops. Both groups administered one drop four times daily for at least three days and until complete symptom resolution. A symptom score (SS) encompassing the five symptoms (redness, lid swelling, foreign body sensation, pain, watering; max score 15) was calculated at baseline, day 3, and day 7.
Results: The study included 230 eyes (120 in group A, 110 in group B). There was a significant reduction in mean total SS at day 3 (2.16 ± 2.42) and day 7 (0.56 ± 1.14) in all eyes compared to at presentation (8.33 ± 2.46). At day 3, there was a lower mean total SS in group A (1.97 ± 2.31) compared to group B (2.36 ± 2.54) which was marginally significant (p = 0.086). At day 7, the proportion of eyes that were symptom-free was similar between groups (70.9%, p = 0.881). A multivariate analysis found that group B (OR = 2.08, p = 0.036) and a higher pain score (OR = 1.50, p = 0.046) were associated with a lack of clinical resolution by day 3.
Conclusion: A course of tobramycin-dexamethasone combination eyedrops after PovI may lead to early symptomatic relief, but recovery was similar to artificial tears by day 7. No significant/sight-threatening complications were observed in any groups.
期刊介绍:
The principal aim of Current Eye Research is to provide rapid publication of full papers, short communications and mini-reviews, all high quality. Current Eye Research publishes articles encompassing all the areas of eye research. Subject areas include the following: clinical research, anatomy, physiology, biophysics, biochemistry, pharmacology, developmental biology, microbiology and immunology.